Mersana Therapeutics, Inc.
Mersana Therapeutics, Inc. (MRSN) is a Biotechnology company in the Healthcare sector, listed on Nasdaq. This page provides the complete earnings calendar, dividend schedule, and financial data for Mersana Therapeutics, Inc. in 2026.
Earnings calendar
Next earnings date
—
Not scheduled
EPS estimate
—
Revenue estimate
—
Past earnings
No earnings history available.
Dividend calendar
No dividend history available.
Company profile
Mersana Therapeutics, Inc., a clinical stage biopharmaceutical company, develops antibody drug conjugates (ADC) for cancer patients with unmet need. It develops XMT-1592, a Dolasynthen ADC targeting NaPi2b-expressing tumor cells, which is in phase I clinical trial for the treatment of ovarian cancer and NSCLC adenocarcinoma. The company also develops XMT-1660, a B7-H4-targeted Dolasynthen ADC candidate; and XMT-2056, an immunosynthen development candidate. It has a strategic research and development partnerships with Merck KGaA and Asana BioSciences, LLC for the development of ADC product candidates utilizing Fleximer. The company was formerly known as Nanopharma Corp. and changed its name to Mersana Therapeutics, Inc. in November 2005. Mersana Therapeutics, Inc. was incorporated in 2001 and is headquartered in Cambridge, Massachusetts.
- Sector
- Healthcare
- Industry
- Biotechnology
- Country
- United States
- Exchange
- Nasdaq
- CEO
- Martin H. Huber
- Employees
- 102
- IPO date
- 28 Jun 2017
- ISIN
- US59045L2051
- Website
- mersana.com
Frequently asked questions
Where is Mersana Therapeutics, Inc. stock listed?
Mersana Therapeutics, Inc. (MRSN) is listed on Nasdaq.